Drug Type CAR-T |
Synonyms Anti BCMA CART cell therapy, BCMA-CART therapy |
Target |
Action modulators |
Mechanism 4-1BB modulators(Tumor necrosis factor receptor superfamily member 9 modulators), BCMA modulators(B-cell maturation protein modulators), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | China | 30 Jan 2023 | |
Relapse multiple myeloma | Phase 1 | China | 01 Mar 2023 | |
Refractory Multiple Myeloma | Phase 1 | China | 01 Jan 2021 | |
Refractory Multiple Myeloma | Phase 1 | China | 01 Jan 2021 |